10-K: Trevi Therapeutics Reports Positive Phase 2a Data and Outlines Future Plans in Annual 10-K Filing

Trevi Therapeutics' 10-K filing highlights positive clinical trial results for Haduvio and outlines the company's strategy for future development and commercialization.

Summary

• Trevi Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing and commercializing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC patients.
• Haduvio acts on the cough reflex arc as a kappa agonist and a mu antagonist (KAMA).
• The company announced positive topline data from its Phase 2a RIVER trial in RCC patients, showing a statistically significant reduction in 24-hour cough frequency.
• Positive topline results were also reported from a human abuse potential (HAP) study, indicating a lower drug liking for oral nalbuphine compared to IV butorphanol.
• Trevi completed enrollment in the Phase 2b CORAL clinical trial for chronic cough in IPF and expects topline results in the second quarter of 2025.
• The company plans to request an end of Phase 2 meeting with the FDA in 2025 and initiate a Phase 3 program in the first half of 2026 for chronic cough in IPF, subject to CORAL trial results.
• Trevi is also planning a Phase 2 clinical trial for chronic cough in non-IPF ILD patients, pending positive data from the CORAL trial and discussions with health authorities.
• The company expects its existing cash, cash equivalents, and marketable securities to fund operations into the second half of 2026.
• Trevi will need substantial additional funding to continue its development programs and commercialization efforts.
• As of December 31, 2024, Trevi had 26 employees, with 16 in research and development and 10 in general management and administration.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results are balanced by the company's ongoing losses, need for additional funding, and competitive landscape. The sentiment is cautiously optimistic.

Positives

• Positive Phase 2a RIVER trial results demonstrate Haduvio's potential efficacy in treating RCC.
• The HAP study suggests a lower abuse potential for oral nalbuphine compared to other opioids.
• Completion of enrollment in the Phase 2b CORAL trial marks a significant milestone in the IPF program.
• The company has a clear strategy for advancing Haduvio through clinical development and commercialization.
• Trevi has sufficient cash runway to fund operations into the second half of 2026.

Negatives

• Trevi has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
• The company is dependent on the successful development and commercialization of Haduvio, its sole product candidate.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The drug label for nalbuphine carries an opioid class label warning for serious respiratory depression.
• The company faces substantial competition, which may result in others developing or commercializing products before or more successfully than Trevi does.

Risks

• The company may need to raise additional capital, and if unable to do so, could be forced to delay, reduce, or abandon product development programs.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent necessary regulatory approvals.
• Adverse events or undesirable side effects caused by Haduvio may delay or prevent marketing approval.
• The company faces substantial competition, which may result in others developing or commercializing products before or more successfully than Trevi does.
• The number of shares of common stock underlying outstanding warrants is significant in relation to the currently outstanding common stock, which could have a negative effect on the market price of the common stock.

Future Outlook

Trevi expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues to develop Haduvio, pursue regulatory approval, and prepare for potential commercial launch. The company will need to obtain substantial additional funding to support its continuing operations and pursue development and commercialization of Haduvio.

Management Comments

• The company expects to request an end of Phase 2 meeting with the FDA in 2025 and initiate a Phase 3 program in the first half of 2026 for chronic cough in IPF, subject to CORAL trial results.
• Trevi is also planning a Phase 2 clinical trial for chronic cough in non-IPF ILD patients, pending positive data from the CORAL trial and discussions with health authorities.
• The company expects its existing cash, cash equivalents, and marketable securities to fund operations into the second half of 2026.

Industry Context

The biopharmaceutical industry is intensely competitive, with Trevi facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies. The company's success depends on its ability to develop and commercialize Haduvio before or more successfully than its competitors.

Comparison to Industry Standards

• The document mentions several competitors and their product candidates in the chronic cough and prurigo nodularis space, including orvepitant (Nerre Therapeutics), ME-015 (Melius Pharma), BI 1839100 (Boehringer Ingelheim), ifenprodil (Seyltx, Inc.), camlipixant (GSK plc), and gefapixant (Merck & Co., Inc.).
• Gefapixant is approved for refractory or unexplained chronic cough in Japan and the E.U., but its application with the FDA was withdrawn.
• The document also notes that Dupixent (dupilumab) was approved by the FDA for the treatment of prurigo nodularis in September 2022, providing a benchmark for treatment in that indication.

Related Party Transactions

• New Enterprise Associates 16, L.P., an existing stockholder of the Company and a related party, as well as an affiliate of NEA, participated in the April 2022 Private Placement.

Stakeholder Impact

• Shareholders: The company's performance and future prospects directly impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs affects job security and opportunities.
• Patients: Successful development of Haduvio could provide a new treatment option for chronic cough.

Next Steps

• Announce topline results from the Phase 2b CORAL clinical trial in the second quarter of 2025.
• Request an end of Phase 2 meeting with the FDA in 2025.
• Initiate a Phase 3 program for chronic cough in IPF in the first half of 2026, subject to Phase 2b CORAL results.
• Conduct a Phase 2 clinical trial for chronic cough in non-IPF ILD patients, pending positive data from the CORAL trial and discussions with health authorities.
• Design and initiate the next planned trial of Haduvio in patients with RCC, following discussions with the FDA.

Key Dates